Note: Descriptions are shown in the official language in which they were submitted.
CA 02379335 2002-O1-15
WO 01/10813 PCT/IB00/01103
1
CRYSTALS OF THE SODIUM SALT OF PRAVASTATIN
The present invention relates to a crystalline form of
the sodium salt of pravastatin, which is known by the
chemical name 1-naphthaleneheptanoid acid, 1,2,6,7,8,8a-
hexahydro-(3,8,6-trihydroxy-2-methyl-8-(2-methyl-1-
oxobutoxy)-, mono sodium salt, which is useful as a
pharmaceutical substance. The present invention further
relates to the method for its preparation and isolation,
to a pharmaceutical formulation containing the sodium
salt of pravastatin in the crystalline form and a
pharmaceutically acceptable carrier, and to the
pharmaceutical method of treatment.
Lovastatin, pravastatin, simvastatin, mevastatin,
atorvastatin, fluvastatin and cervastatin and derivatives
and analogs thereof are known as HMG-CoA reductase
inhibitors and are used as antihypercholesterolemic
agents. The majority of them are produced by fermentation
using microorganisms of different species identified as
species belonging to Aspergillus, Monascus, Nocardia,
Amycolatopsis, Mucor or Penicillium genus, some are
obtained by treating the fermentation products using the
methods of chemical synthesis (simvastatin) or they are
the products of total chemical synthesis (fluvastatin,
atorvastatin and cervastatin).
Processes for the preparation of the sodium salt of
pravastatin in a solid form known from the prior art
comprise, for example, the step of lyophilisation. After
lyophilisation only the solvent is removed but impurities
remain together with the sodium salt of pravastatin.
Apart from the aforementioned, lyophilisation is not very
economical in large-scale production operations. During
precipitation due to nonselectivity of the process,
COfVL~~~#~Tt'Jl~d ~P'Y
W~ 01/10813 CA 02379335 2002-O1-15 PCT/IB00/01103
- 2 -
impurities precipitate together with the desired
substance. Compared to the both aforementioned processes
for the preparation of pharmaceutical substances in the
solid form, crystallization is the only selective process
wherein the molecules of the desired substance are
selectively incorporated into the crystal matrix.
Possibility of inclusion of impurities into the crystal
is minimal because only small size molecules are able to
incorporate into intermolecular space inside a crystal
(related impurities, which are usually within the desired
substance size range may only be incorporated into this
space with great difficulty), incorporation of other
molecules into the crystal matrix is not favoured
thermodynamically.
The advantage of substances in the crystal structures
over those in amorphous structures is that their physical
as well as chemical parameters are better defined and
they are more stable. The latter is of particular
importance for the substances which in their nature are
unstable and sensitive to different ambient influences,
such as light, pH, atmosphere and temperature.
Pravastatin sodium is particularly sensitive to these
negative influences.
It has been known that thus far the sodium salt of
pravastatin may only be present in an amorphous form. The
Merck Index 1996 describes the sodium salt of pravastatin
as an amorphous substance.
Methods for the preparation of the sodium salt of
pravastatin described in many patents, for example US
Pat. No. 44,537,859, US Pat. No. 4,448,979, US Pat. No.
4,410,629 and US Pat. No. 4,346,227, afford only the
preparation of an amorphous form. In the methods
disclosed, after separation on the chromatographic
W~ 01/10813 CA 02379335 2002-O1-15 PCT/IB00/01103
- 3 -
columns, the fractions obtained comprising the sodium
salt of pravastatin are lyophilized and the sodium salt
in a solid - amorphous form is obtained.
The WO-A-98/45410 discloses that after the sodium salt of
pravastatin is purified using reverse-phase
chromatography, alleged crystals may be obtained by
precipitation in the ethanol/ethyl acetate mixture;
however, the experiments we have carried out suggest that
this combination of the solvents affords the preparation
of pravastatin in the amorphous form and not in the
crystalline form.
It is an object of the present invention to provide the
sodium salt of pravastatin which is improved in purity
and stability compared to the salts described in the
prior art mentioned above.
Further, it is another object of the present invention to
provide a process for the preparation of such a sodium
salt of pravastatin.
These and further objects are accomplished by the present
invention.
In a first aspect, the present invention provides the
sodium salt of pravastatin in a crystalline form.
Furthermore, the present invention also provides the
sodium salt of pravastatin in a specific crystalline
form, wherein the crystals in an X-ray diffraction
measurement produce a signal sufficiently comparable to
that illustrated in the diffractogram shown in Figure 2.
In a second aspect, the present invention provides a
process for the preparation of the sodium salt of
pravastatin in a crystalline form comprising the steps
VV~ 01/10813 CA 02379335 2002-O1-15
PCT/IB00/01103
- 4 -
of: (a) dissolution of the sodium salt of pravastatin in
a lower aliphatic alcohol; (b) addition of ethyl acetate
to the alcoholic solution of the sodium salt of
pravastatin; (c) cooling of said alcohol/ethyl acetate
mixture; and (d) crystallization.
According to a third aspect of the present invention,
there is further provided a pharmaceutical formulation
containing the sodium salt of pravastatin in the
aforementioned crystalline forms.
The crystalline sodium salt of pravastatin according to
the present invention is particularly suitable for the
preparation of pharmaceutical products for the treatment
of hypercholesterolemia and hyperlipidemia.
In the following, drawings will be briefly described.
Figure 1: Diffractogram of a conventional amorphous
sodium salt of pravastatin which is
commercially available, scanned on the X-ray
powder diffractometer within 2 to 42° 28 range
with a 0.025° 28 step and an integration time
of 1 second/step.
Figure 2: Diffractogram of crystals of the sodium salt
of pravastatin prepared according to Example 2
of the present invention, which are scanned on
the X-ray powder diffractometer within 2 to
48° 28 range with a 0.035° 28 step and an
integration time of 1 second/step.
WO ~1/1~813 CA 02379335 2002-O1-15 PCT/IB00/01103
- 5 -
Figure 3: Image of the amorphous sodium salt of
pravastatin used for the X-ray diffraction
measurement shown in Fig. l, which is obtained
under the microscope under 400-fold
magnification.
Figure 4: Image of crystals of the sodium salt of
pravastatin prepared according to Example 2 of
the present invention, obtained under the
microscope under 400-fold magnification.
X-ray diffraction measurements were carried out with a
X-ray powder diffractometer (Phillips PW 1710) using a
Cu-KG (20 mA, 40 kV, ~, = 1.5406 A) light source. For
microscopic observations, an OLYMPUS BX 50F microscope
with a CCD Sonny DXC-950-P camera was used with 400-fold
magnification.
In the following, the present invention will be
illustrated in more detail by the description of
preferred embodiments.
In our research work we have surprisingly found that by
suitable selection of the solvents and adequate order of
their use the sodium salt of pravastatin in a form having
an improved crystallinity, relative to the conventional
solid form, can be prepared. Thus, in contrast to the
white appearance of the pravastatin sodium solid
described in the WO-A-98/45410, it is possible according
to the present invention to achieve crystals exhibiting a
colorless or pale yellow appearance, which clearly
indicates the improved crystallinity and, thus, the
clearly crystalline form of the sodium salt of
pravastatin provided by the present invention.
CA 02379335 2002-O1-15
WO 01/10813 PCT/IB00/01103
- 6 -
Other physical properties of the crystals of the
pravastatin sodium of the present invention further
indicate the improved crystallinity obtained. Firstly,
the crystals according to the present invention can be
preferably obtained in the form of needles, sometimes in
the form of radiating clusters. Such crystal shape can be
readily observed under the microscope, for example when
the observation is carried out under 400-fold
magnification (see Fig. 4). By contrast, conventionally
available amorphous pravastatin sodium appear in the
shape of granular particles (see Fig. 3).
Secondly, the melting point of the pravastatin sodium
crystals according to the present invention is preferably
between 170 and 174°C, more preferably between 172 and
174°C. This melting point range achieved in the present
invention is very small for such a complicated chemical
structure and confirms the high crystallinity of the
pravastatin sodium crystals obtained.
Thirdly, a further characteristic feature of the
crystalline pravastatin sodium according to the present
invention is that the signal obtained in an X-ray
diffraction measurement (Cu-Ka, 28) have sharp and
distinct peaks. In particular, the shape of the X-ray
diffraction peaks of pravastatin sodium according to the
present invention are defined by a small half-value
width, which confirms a high degree of crystallinity. The
term "half-value width" means the value of the 2B-range
of one peak at the half height or magnitude of the
respective peak. Accordingly, the signals obtained by
these measurements comprise distinct peaks (28) having a
half-value width preferably below 2°, more preferably
below 1°, and most preferably below 0,5°
W~ 01/10813 CA 02379335 2002-O1-15 PCT/IB00/01103
- 7 _
Exemplary crystals of pravastatin sodium prepared
according the present invention produce a diffractogram
in an X-ray diffraction measurement that is shown in
Figure 2. Due to i-ts particularly improved crystallinity
and, thus, purity and stability, such pravastatin sodium
crystals which, in an X-ray diffraction measurement
(Cu-K~), produce a signal sufficiently comparable to
that, preferably essentially as that illustrated in the
diffractogram shown in Figure 2, constitute preferred
embodiments of the present invention. Unit cells of this
crystal could not be determined because of its size and
high background at the angles > 20° 28. Comparison of the
recorded diffractogram with the reference from the PDF
and CSD databases (PDF - "Powder Diffraction File issued
by "International Center for Diffraction Data", 12 Campus
Boulevard, Newtown Square, PA 19073-3273 USA; CSD -
"Cambridge Structural Database System" issued by
"Cambridge Crystallographic Data Centre", 12 Union Road,
Cambridge CB2 lEZ, the United Kingdom) has shown that the
crystals of the sodium salt of pravastatin according to
the present invention are really a novel and thus only
known crystalline form of the sodium salt of pravastatin.
For comparison, a diffractogram of amorphous pravastatin
sodium which is commercially available is shown in
Figure 1.
The process for the preparation of crystals according to
the present invention as described above comprises the
following steps:
(a) Providing a solution containing pravastatin and
sodium can ons in a lower aliphatic alcohol. This is
suitably carried out by dissolution of an solid and/or
amorphous sodium salt of pravastatin in a lower aliphatic
alcohol having preferably 1 to 4 carbon atoms. More
CA 02379335 2002-O1-15
WO 01/10813 PCT/IB00/01103
g _
preferably, the alcohol used for the dissolution of
pravastatin sodium is ethanol or methanol. The best
crystallization results have been achieved when preparing
a solution of pravastatin sodium in methanol.
(b) Addition of ethyl acetate into the alcoholic
solution, preferably while the alcoholic solution
obtained in step (a) is stirred continually. The addition
of ethyl acetate into the alcoholic solution of
pravastatin sodium is preferably carried out slowly,
while the addition may be continuously or stepwise.
(c) Cooling of the resulting alcohol/ethyl acetate
mixture.
(d) Crystallization.
In step (d), from the cooled mixture crystals of the
sodium salt of pravastatin, which preferably have a
colorless or pale yellow appearance and are in the form
of needles or radiating clusters, are formed.
Additionally, the crystals obtained by this process may
preferably be filtered, ethyl acetate washed and dried.
The crystallization is carried out advantageously if the
initial concentration of the sodium salt of pravastatin
in the aliphatic alcohol used for the dissolution -is
preferably between 0.03 and 0.3 g/ml, more preferably
between 0.05 and 0.2 g/ml, particularly about 0.1 g/ml,
and if the volume of added ethyl acetate in step (b) does
preferably not exceed the 15-fold volume, more preferably
the 10-fold volume of the starting solution of the sodium
salt of pravastatin in the aliphatic alcohol.
WU 01/10813 CA 02379335 2002-0l-15 PCT/IB00/01103
- 9 -
Furthermore, to achieve a higher crystallization rate,
the preferred temperature of crystallization is below
15°C, more preferably below 10°C, particularly about 8°C.
For enforcing further crystallization, it is preferred to
carry out the process according to the invention with
additional steps of:
(e) Further adding ethyl acetate to the mixture of
step (d). This is done after an appropriate period of a
first crystallization stage where crystallization occurs.
(f) then, crystallization of pravastatin sodium is
continued while cooling.
With such an additional crystallization stage the yield
of crystalline pravastatine sodium can be increased,
normally by 5 to 10 0.
The volume of ethyl acetate additionally added to the
cooled mixture in step (e) is preferably in the range of
from 25 to 75 o by volume, more preferably from 40 to
60 o by volume based on the volume of ethyl acetate added
in step (b) .
Furthermore, the crystals are preferably formed within a
total crystallization time of 3 to 20 hours. More
preferably, the total crystallization time is between 4
and 12 hours, particularly about 4 hours.
The present invention also relates to pharmaceutical
formulations containing the sodium salt of pravastatin in
the form of crystals. The pharmaceutical formulation is
present in the form which is suitable for oral and
parenteral administration, respectively, and is useful
for the treatment of hypercholesterolemia and
W~ 01/10813 CA 02379335 2002-O1-15
PCT/IB00/01103
- 10 -
hyperlipidemia. The pharmaceutical formulation of the
present invention is available in the form of tablets,
capsules, granules and suppositories as well as in the
form of suspensions.
The pharmaceutical formulation of this invention may
comprise, in addition to the sodium salt of pravastatin,
one or more fillers, such as microcrystalline cellulose,
lactose, sugars, starches, modified starch, mannitol,
sorbitol and other polyols, dextrin, dextran and
maltodextrin, calcium carbonate, calcium phosphate and/or
hydrogen phosphate, sulphate, one or more binders, such
as lactose, starches, modified starch, dextrin, dextran
and maltodextrin, microcrystalline cellulose, sugars,
polyethylene glycols, hydroxypropyl cellulose,
hydroxypropyl methylcellulose, ethylcellulose,
hydroxyethyl cellulose, methylcellulose, carboxymethyl
cellulose, gelatin, acacia gum, tragacanth,
polyvinylpyrrolidone, magnesium aluminium silicate, one
or more disintegrating agents such as croscarmellose
sodium, cross-linked polyvinylpyrrolidone, cross-linked
carboxymethyl starch, starches and microcrystalline
cellulose, magnesium aluminium silicate, polyacrylin
potassium, one or more different glidants such as
magnesium stearate, calcium stearate, zinc stearate,
calcium behenate, sodium stearyl fumarate, talc,
magnesium trisilicate, stearic acid, palmitic acid,
carnauba wax, silicon dioxide, one or more buffering
agents such as sodium or potassium citrate, sodium
phosphate, dibasic sodium phosphate, calcium carbonate,
hydrogen phosphate, phosphate, sulphate, sodium or
magnesium carbonate, sodium ascorbinate, benzoate, sodium
or potassium hydrogen carbonate, lauryl sulphate, or
mixtures of such buffering agents.
W~ 01/10813 CA 02379335 2002-O1-15 PCT/IB00/01103
- 11 -
If required any, the formulation may also comprise
surfactants and other conventional components for solid,
pharmaceutical formulations such as coloring agents,
lakes, aromas and adsorbents. As surfactants the
following may be used: ionic surfactants, such as sodium
lauryl sulphate or non-ionic surfactants such as
different poloxamers (polyoxyethylene and
polyoxypropylene copolymers), natural or synthesized
lecithins, esters of sorbitan and fatty acids (such as
Span°, manufactured by Atlas Chemie), esters of
polyoxyethylenesorbitan and fatty acids (such as Tween°,
manufactured by Atlas Chemie), polyoxyethylated
hydrogenated castor oil (such as Cremophor°, manufactured
by BASF), polyoxyethylene stearates (such as Brij°,
manufactured by Atlas Chemie), dimethylpolysiloxane or
any combination of the above mentioned surfactants.
If the solid pharmaceutical formulation is in the form of
coated tablets, the coating may be prepared from at least
one film-former such as hydroxypropyl methylcellulose,
hydroxypropyl cellulose, at least from one plasticizer
such as polyethylene glycols, dibutyl sebacate, triethyl
citrate, and other pharmaceutical auxiliary substances
conventional for film coatings, such as pigments, fillers
and others.
The pharmaceutical formulation can be prepared by
conventional formulation methods known to those skilled
in the art.
The present invention is illustrated but by no means
limited by the following examples.
WO 01/10813 CA 02379335 2002-O1-15 PCT/IB00/(11103
- 12 -
Example 1
The sodium salt of pravastatin (1 g) was dissolved in
methanol (10 ml) and while stirring ethyl acetate was
added. The resulting clear yellow solution was cooled to
8°C and allowed to stand overnight. Formed radiating
clusters of thin, long needle-like crystals were
filtered, washed with ethyl acetate (20 ml) and dried.
Yield: 0.87 g of pale yellow crystals, melting point
172 - 174°C.
Example 2
The sodium salt of pravastatin (2 g) was dissolved in
methanol (20 ml) and while stirring ethyl acetate (80 ml)
was added. The clear, slightly yellow solution was cooled
to 8°C and allowed to stand for 4 hours. Formed radiating
clusters of thin, long needle-like crystals were
filtered, washed with ethyl acetate (20 ml) and dried.
Yield: 1.53 g of colorless crystals, melting point
172 - 174°C.
Example 3
The sodium salt of pravastatin (2 g) was dissolved in
methanol (20 ml) and while stirring ethyl acetate
(150 ml) was added. The resulting clear, slightly yellow
solution was cooled to 8°C and allowed to stand for
4 hours. Formed radiating clusters of thin, long needle-
like crystals were filtered, washed with ethyl acetate
(20 ml) and dried. Yield: 1.66 g of colorless crystals,
melting point 172 - 174°C.
Example 4
The sodium salt of pravastatin (2 g) was dissolved in
methanol (20 ml) and while stirring ethyl acetate
CA 02379335 2002-O1-15
WO 01/10813 PCT/IB00/01103
- 13 -
(170 ml) was added. The resulting clear, slightly yellow
solution was cooled to 8°C and allowed to stand for
4 hours. Formed radiating clusters of thin, long needle-
like crystals were- filtered, washed with ethyl acetate
(20 ml) and dried. Yield: 1.75 g of colorless crystals,
melting point 172 - 174°C.
Example 5
The sodium salt of pravastatin (2 g) was dissolved in
methanol (12 ml) and while stirring ethyl acetate
(100 ml) was added. The resulting clear, slightly yellow
solution was cooled to 8°C and allowed to stand for
1 hour. After that further ethyl acetate (60 ml) was
added, so the pravastatin still dissolved in the solution
was forced to crystallize. After 2 hours at 8°C the
formed radiating clusters of thin, long needle-like
crystals were filtered, washed with ethyl acetate (20 ml)
and dried. Yield: 1.85 g of colorless crystals, melting
point 172 - 174°C.
